ViroPharma Lied About Antibiotic Exclusivity, Investor Says

Law360, New York (May 18, 2012, 7:21 PM EDT) -- A shareholder on Wednesday filed a proposed class action against ViroPharma Inc. seeking damages for stock losses allegedly sustained after the company wrongly led investors to believe it had secured three years of market exclusivity for its signature gastrointestinal antibiotic.

In a suit filed in Pennsylvania federal court, the shareholder accuses the company of misleading investors with statements in December that its antibiotic brand, Vancocin, would qualify for three years of market exclusivity thanks to a new condition of use established for the drug by the...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

CASTRO v. VIROPHARMA INCORPORATED et al


Case Number

2:12-cv-02714

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Securities/Commodities

Judge

C. DARNELL JONES, II

Date Filed

May 17, 2012

Law Firms

Companies

Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.